C1q-Binding Antibodies for Selective Macrophage M2 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches targeting C1q primarily focus on inhibiting the activation of the classical complement cascade, neglecting the non-complement-related functions of C1q, which are implicated in various diseases such as neurodegenerative disorders, autoimmune diseases, and cancer.
Innovation Solution
Development of C1q-binding molecules that inhibit non-complement-related functions of C1q, such as macrophage polarization to the M2 phenotype, IL-10 production, and efferocytosis, while preserving complement-related activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If therapeutic approaches focus on inhibiting activation of the classical complement cascade, then complement-related diseases are treated, but non-complement-related diseases involving C1q remain untreated
Solution Approach 1:
The patent segments C1q's functions into two distinct pathways: complement-related functions (handled by existing therapies) and non-complement-related functions (targeted by the new antibody). This segmentation allows selective inhibition of pathological M2 macrophage polarization without affecting beneficial complement cascade activation, thereby expanding therapeutic coverage to non-complement diseases while maintaining treatment specificity
Solution Approach 2:
The antibody of the patent exhibits local quality by selectively binding to C1q regions involved in M2 macrophage polarization rather than regions required for complement cascade activation. This localized binding approach enables the antibody to inhibit specific pathological functions (M2 polarization in fibrosis, cancer, and neurological diseases) while preserving other physiological functions of C1q, thus expanding therapeutic applicability without requiring complex multi-target interventions
2Reliability
If C1q binding molecules inhibit M2 macrophage polarization, then diseases associated with M2 macrophages are treated, but complement cascade activation may be affected
Solution Approach 1:
The antibody is designed to bind specifically to epitopes on C1q that are involved in M2 macrophage polarization but not in complement cascade activation. This localized binding ensures selective inhibition of pathological M2 polarization processes in diseases like fibrosis and cancer, while preserving the integrity and function of the complement cascade, thereby achieving reliable disease treatment without causing harmful complement disruption
Solution Approach 2:
Instead of broadly inhibiting C1q function as done by existing complement cascade inhibitors, the patent inverts the approach by selectively preserving complement activation while inhibiting non-complement functions. This inverted strategy achieves superior therapeutic reliability by treating M2-related diseases without the harmful side effect of complement dysfunction
Data Source
Figure 1
Figure 1
Figure 1
AI summary
Antigen binding molecules that bind to C1q are disclosed herein. Also disclosed are compositions comprising such antigen binding molecules, and uses and methods using the same.